- Home
- ASM vs MNPR Comparison
ASM vs MNPR Comparison
Compare ASM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- MNPR
- Stock Information
- Founded
- ASM 1968
- MNPR 2014
- Country
- ASM Canada
- MNPR United States
- Employees
- ASM N/A
- MNPR N/A
- Industry
- ASM Metal Mining
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ASM Basic Materials
- MNPR Health Care
- Exchange
- ASM Nasdaq
- MNPR Nasdaq
- Market Cap
- ASM 252.5M
- MNPR 244.1M
- IPO Year
- ASM N/A
- MNPR 2019
- Fundamental
- Price
- ASM $1.88
- MNPR $40.33
- Analyst Decision
- ASM Strong Buy
- MNPR Strong Buy
- Analyst Count
- ASM 2
- MNPR 5
- Target Price
- ASM $2.00
- MNPR $49.60
- AVG Volume (30 Days)
- ASM 3.2M
- MNPR 30.6K
- Earning Date
- ASM 03-11-2025
- MNPR 05-08-2025
- Dividend Yield
- ASM N/A
- MNPR N/A
- EPS Growth
- ASM 1287.60
- MNPR N/A
- EPS
- ASM 0.06
- MNPR N/A
- Revenue
- ASM $66,178,000.00
- MNPR N/A
- Revenue This Year
- ASM $24.16
- MNPR $34.06
- Revenue Next Year
- ASM $21.17
- MNPR N/A
- P/E Ratio
- ASM $32.88
- MNPR N/A
- Revenue Growth
- ASM 50.78
- MNPR N/A
- 52 Week Low
- ASM $0.59
- MNPR $1.72
- 52 Week High
- ASM $2.00
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- ASM 62.86
- MNPR 56.65
- Support Level
- ASM $1.77
- MNPR $36.80
- Resistance Level
- ASM $1.96
- MNPR $43.00
- Average True Range (ATR)
- ASM 0.15
- MNPR 5.32
- MACD
- ASM 0.01
- MNPR 0.94
- Stochastic Oscillator
- ASM 82.35
- MNPR 63.41
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.